AdaptHealth (AHCO) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

AHCO Stock Forecast


AdaptHealth stock forecast is as follows: an average price target of $20.83 (represents a 113.86% upside from AHCO’s last price of $9.74) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

AHCO Price Target


The average price target for AdaptHealth (AHCO) is $20.83 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $12.00. This represents a potential 113.86% upside from AHCO's last price of $9.74.

AHCO Analyst Ratings


Buy

According to 4 Wall Street analysts, AdaptHealth's rating consensus is 'Buy'. The analyst rating breakdown for AHCO stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

AdaptHealth Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2024David MacDonaldTruist Financial$12.00$9.8022.45%23.20%
Nov 06, 2024Eric ColdwellRobert W. Baird$14.00$9.0754.36%43.74%
Sep 23, 2024Eric ColdwellRobert W. Baird$16.00$11.4240.11%64.27%
Aug 08, 2024Kevin CaliendoUBS$13.00$9.5336.41%33.47%
Sep 20, 2022-Deutsche Bank$28.00$21.8128.38%187.47%
Sep 19, 2022-Truist Financial$28.00$20.9833.46%187.47%
Aug 10, 2022-RBC Capital$29.00$22.2430.40%197.74%
Aug 10, 2022-Leerink Partners$29.00$22.2430.40%197.74%
Jul 26, 2022David MacDonaldTruist Financial$24.00$21.0014.29%146.41%
Row per page
Go to

The latest AdaptHealth stock forecast, released on Nov 15, 2024 by David MacDonald from Truist Financial, set a price target of $12.00, which represents a 22.45% increase from the stock price at the time of the forecast ($9.80), and a 23.20% increase from AHCO last price ($9.74).

AdaptHealth Price Target by Period


1M3M12M
# Anlaysts234
Avg Price Target$13.00$14.00$13.75
Last Closing Price$9.74$9.74$9.74
Upside/Downside33.47%43.74%41.17%

In the current month, the average price target of AdaptHealth stock is $13.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 33.47% increase as opposed to AdaptHealth's last price of $9.74. This month's average price target is down -7.14% compared to last quarter, and down -5.45% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 08, 2024UBSBuyBuyHold
May 15, 2024UBSBuyBuyHold
Mar 04, 2024UBSBuyBuyHold
Mar 04, 2024RBC CapitalUnderperformUnderperformHold
Sep 20, 2022Deutsche BankBuyBuyHold
Sep 19, 2022SusquehannaBuyBuyHold
Aug 10, 2022RBC CapitalOutperformOutperformHold
Aug 10, 2022SVB LeerinkOutperformOutperformHold
Feb 18, 2022SVB LeerinkOutperformOutperformHold
Row per page
Go to

AdaptHealth's last stock rating was published by UBS on Aug 08, 2024. The company gave AHCO a "Buy" rating, the same as its previous rate.

AdaptHealth Financial Forecast


AdaptHealth Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
Revenue------------$858.23M$804.03M$793.29M$744.63M$780.28M$557.65M$727.61M$706.20M$702.11M$653.29M$617.02M$482.12M$348.43M$284.40M$232.12M$191.44M$529.64M
Avg Forecast$916.74M$882.22M$869.26M$832.32M$871.24M$839.10M$827.28M$803.18M$828.35M$809.32M$802.62M$769.87M$825.45M$796.60M$765.17M$756.47M$788.13M$737.93M$724.22M$651.42M$689.92M$638.74M$574.03M$486.34M$323.10M$265.25M$196.28M$177.41M$142.25M
High Forecast$944.47M$908.91M$895.55M$857.50M$897.59M$864.48M$852.30M$822.37M$869.18M$812.85M$802.62M$769.87M$830.51M$796.60M$788.31M$779.35M$811.97M$737.93M$724.22M$651.42M$689.92M$638.74M$574.03M$486.34M$323.10M$265.25M$196.28M$177.41M$142.25M
Low Forecast$890.47M$856.94M$844.36M$808.47M$846.28M$815.06M$803.57M$766.00M$808.97M$805.79M$802.62M$769.87M$817.52M$796.60M$743.24M$734.79M$765.55M$737.93M$724.22M$651.42M$689.92M$638.74M$574.03M$486.34M$323.10M$265.25M$196.28M$177.41M$142.25M
# Analysts22221114633475632222345663332
Surprise %------------1.04%1.01%1.04%0.98%0.99%0.76%1.00%1.08%1.02%1.02%1.07%0.99%1.08%1.07%1.18%1.08%3.72%

AdaptHealth's average Quarter revenue forecast for Mar 24 based on 4 analysts is $769.87M, with a low forecast of $769.87M, and a high forecast of $769.87M. AHCO's average Quarter revenue forecast represents a -10.30% decrease compared to the company's last Quarter revenue of $858.23M (Dec 23).

AdaptHealth EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts22221114633475632222345663332
EBITDA------------$-227.64M$-441.83M$67.48M$118.81M$50.44M$145.02M$137.39M$122.92M$135.80M$164.32M$178.38M$63.73M$-41.92M$32.03M$31.71M$25.63M$-6.43M
Avg Forecast$89.18M$85.82M$84.56M$80.97M$84.75M$81.63M$80.48M$78.13M$80.58M$78.73M$78.08M$252.68M$80.30M$77.49M$74.43M$229.70M$201.67M$94.93M$93.17M$208.82M$88.75M$82.17M$73.85M$124.69M$41.56M$34.12M$25.25M$46.85M$-19.86M
High Forecast$91.88M$88.42M$87.12M$83.42M$87.32M$84.10M$82.91M$80.00M$84.55M$79.07M$78.08M$303.21M$80.79M$77.49M$76.69M$275.65M$242.00M$94.93M$93.17M$250.59M$88.75M$82.17M$73.85M$149.63M$41.56M$34.12M$25.25M$56.22M$-15.88M
Low Forecast$86.62M$83.36M$82.14M$78.65M$82.33M$79.29M$78.17M$74.52M$78.70M$78.39M$78.08M$202.14M$79.53M$77.49M$72.30M$183.76M$161.33M$94.93M$93.17M$167.06M$88.75M$82.17M$73.85M$99.75M$41.56M$34.12M$25.25M$37.48M$-23.83M
Surprise %-------------2.83%-5.70%0.91%0.52%0.25%1.53%1.47%0.59%1.53%2.00%2.42%0.51%-1.01%0.94%1.26%0.55%0.32%

5 analysts predict AHCO's average Quarter EBITDA for Sep 23 to be $77.49M, with a high of $77.49M and a low of $77.49M. This is 14.84% upper than AdaptHealth's previous annual EBITDA (Jun 23) of $67.48M.

AdaptHealth Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts22221114633475632222345663332
Net Income------------$-254.50M$-454.08M$13.98M$15.71M$-1.57M$16.12M$14.03M$41.75M$23.47M$58.09M$79.11M$-3.97M$-65.87M$-2.49M$4.03M$-158.16K$-15.00M
Avg Forecast$69.64M$51.87M$47.48M$37.09M$47.62M$34.78M$32.33M$23.40M$37.21M$26.03M$26.24M$70.72M$26.28M$26.98M$17.97M$64.30M$34.07M$41.70M$39.97M$58.45M$51.52M$47.01M$34.11M$-7.76M$26.62M$14.00M$15.42M$-289.16K$-46.28M
High Forecast$72.38M$53.91M$49.34M$38.55M$49.50M$36.14M$33.60M$25.74M$43.98M$26.15M$26.60M$84.87M$30.23M$27.08M$18.68M$77.15M$40.88M$41.70M$39.97M$70.14M$51.52M$47.01M$34.11M$-6.21M$26.62M$14.00M$15.42M$-231.32K$-37.03M
Low Forecast$67.04M$49.94M$45.71M$35.71M$45.85M$33.48M$31.13M$21.06M$31.57M$25.92M$25.89M$56.58M$18.40M$26.87M$17.30M$51.44M$27.26M$41.70M$39.97M$46.76M$51.52M$47.01M$34.11M$-9.31M$26.62M$14.00M$15.42M$-346.99K$-55.54M
Surprise %-------------9.68%-16.83%0.78%0.24%-0.05%0.39%0.35%0.71%0.46%1.24%2.32%0.51%-2.47%-0.18%0.26%0.55%0.32%

AdaptHealth's average Quarter net income forecast for Sep 23 is $26.98M, with a range of $26.87M to $27.08M. AHCO's average Quarter net income forecast represents a 93.01% increase compared to the company's last Quarter net income of $13.98M (Jun 23).

AdaptHealth SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts22221114633475632222345663332
SG&A------------$47.29M$45.20M$50.08M$47.52M$37.45M$40.68M$42.55M$41.44M$34.92M$33.01M$42.95M$56.63M$31.60M$26.31M$17.09M$14.35M$53.21M
Avg Forecast$64.27M$61.85M$60.94M$58.35M$61.08M$58.83M$58.00M$56.31M$58.08M$56.74M$56.27M$70.21M$57.87M$55.85M$53.65M$63.82M$51.86M$51.36M$50.41M$58.02M$48.02M$44.46M$39.96M$110.80M$22.49M$18.46M$13.66M$26.23M$9.90M
High Forecast$66.22M$63.72M$62.79M$60.12M$62.93M$60.61M$59.75M$57.66M$60.94M$56.99M$56.27M$84.25M$58.23M$55.85M$55.27M$76.59M$62.23M$51.36M$50.41M$69.63M$48.02M$44.46M$39.96M$132.96M$22.49M$18.46M$13.66M$31.48M$9.90M
Low Forecast$62.43M$60.08M$59.20M$56.68M$59.33M$57.14M$56.34M$53.70M$56.72M$56.49M$56.27M$56.16M$57.32M$55.85M$52.11M$51.06M$41.49M$51.36M$50.41M$46.42M$48.02M$44.46M$39.96M$88.64M$22.49M$18.46M$13.66M$20.98M$9.90M
Surprise %------------0.82%0.81%0.93%0.74%0.72%0.79%0.84%0.71%0.73%0.74%1.07%0.51%1.41%1.42%1.25%0.55%5.37%

AdaptHealth's average Quarter SG&A projection for Mar 24 is $70.21M, based on 4 Wall Street analysts, with a range of $56.16M to $84.25M. The forecast indicates a 48.45% rise compared to AHCO last annual SG&A of $47.29M (Dec 23).

AdaptHealth EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts22221114633475632222345663332
EPS------------$-1.91$-3.37$0.10$0.11$-0.01$0.11$0.10$0.29$0.18$0.40$0.56$-0.04$-0.47$-0.04$0.09$-0.00$-0.10
Avg Forecast$0.51$0.38$0.35$0.27$0.35$0.25$0.24$0.17$0.27$0.19$0.19$0.06$0.19$0.20$0.13$0.10$0.31$0.31$0.29$0.21$0.38$0.35$0.25$0.25$0.20$0.10$0.11$0.12$0.06
High Forecast$0.53$0.39$0.36$0.28$0.36$0.26$0.25$0.19$0.32$0.19$0.19$0.06$0.22$0.20$0.14$0.10$0.32$0.31$0.29$0.21$0.38$0.35$0.25$0.25$0.20$0.10$0.11$0.12$0.06
Low Forecast$0.49$0.37$0.33$0.26$0.34$0.25$0.23$0.15$0.23$0.19$0.19$0.05$0.13$0.20$0.13$0.09$0.30$0.31$0.29$0.21$0.38$0.35$0.25$0.25$0.20$0.10$0.11$0.12$0.06
Surprise %-------------9.92%-17.06%0.76%1.13%-0.04%0.36%0.34%1.41%0.48%1.16%2.23%-0.16%-2.40%-0.39%0.79%-0.03%-1.55%

According to 5 Wall Street analysts, AdaptHealth's projected average Quarter EPS for Sep 23 is $0.20, with a low estimate of $0.20 and a high estimate of $0.20. This represents a 97.59% increase compared to AHCO previous annual EPS of $0.10 (Jun 23).

AdaptHealth Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
APYXApyx Medical$1.28$8.50564.06%Buy
SGHTSight Sciences$3.77$9.00138.73%Hold
AHCOAdaptHealth$9.74$20.83113.86%Buy
LUNGPulmonx$6.00$11.9398.83%Buy
KIDSOrthoPediatrics$24.32$39.6062.83%Buy
NPCENeuroPace$9.18$12.8840.31%Buy
LIVNLivaNova$51.36$70.5037.27%Buy
AVNSAvanos Medical$17.80$23.0029.21%Hold
OFIXOrthofix Medical$18.73$24.0028.14%-
AORTArtivion$26.93$30.6013.63%Buy
FNAParagon 28$10.50$11.509.52%Buy
ITGRInteger$133.52$138.003.36%Buy
SRDXSurmodics$39.19$39.500.79%Buy

AHCO Forecast FAQ


Is AdaptHealth a good buy?

Yes, according to 4 Wall Street analysts, AdaptHealth (AHCO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of AHCO's total ratings.

What is AHCO's price target?

AdaptHealth (AHCO) average price target is $20.83 with a range of $12 to $29, implying a 113.86% from its last price of $9.74. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AdaptHealth stock go up soon?

According to Wall Street analysts' prediction for AHCO stock, the company can go up by 113.86% (from the last price of $9.74 to the average price target of $20.83), up by 197.74% based on the highest stock price target, and up by 23.20% based on the lowest stock price target.

Can AdaptHealth stock reach $15?

AHCO's average twelve months analyst stock price target of $20.83 supports the claim that AdaptHealth can reach $15 in the near future.

What is AdaptHealth's current price target trend?

2 Wall Street analysts forecast a $13 price target for AdaptHealth (AHCO) this month, up 33.47% from its last price of $9.74. Compared to the last 3 and 12 months, the average price target increased by 43.74% and increased by 41.17%, respectively.

What are AdaptHealth's analysts' financial forecasts?

AdaptHealth's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.34B (high $3.44B, low $3.23B), average EBITDA is $324.99M (high $334.32M, low $314.3M), average net income is $138.13M (high $144.99M, low $131.52M), average SG&A $234.22M (high $240.95M, low $226.52M), and average EPS is $1.01 (high $1.06, low $0.963). AHCO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.5B (high $3.61B, low $3.4B), average EBITDA is $340.53M (high $350.83M, low $330.77M), average net income is $206.09M (high $214.19M, low $198.41M), average SG&A $245.42M (high $252.85M, low $238.39M), and average EPS is $1.51 (high $1.57, low $1.45).

Did the AHCO's actual financial results beat the analysts' financial forecasts?

Based on AdaptHealth's last annual report (Dec 2023), the company's revenue was $3.2B, beating the average analysts forecast of $3.14B by 1.80%. Apple's EBITDA was $-541M, missing the average prediction of $461.93M by -217.01%. The company's net income was $-679M, missing the average estimation of $135.53M by -600.94%. Apple's SG&A was $190.09M, missing the average forecast of $231.19M by -17.78%. Lastly, the company's EPS was $-5.05, missing the average prediction of $0.619 by -916.29%. In terms of the last quarterly report (Dec 2023), AdaptHealth's revenue was $858.23M, beating the average analysts' forecast of $825.45M by 3.97%. The company's EBITDA was $-228M, missing the average prediction of $80.3M by -383.49%. AdaptHealth's net income was $-255M, missing the average estimation of $26.28M by -1068.35%. The company's SG&A was $47.29M, missing the average forecast of $57.87M by -18.28%. Lastly, the company's EPS was $-1.91, missing the average prediction of $0.193 by -1092.21%